Citius Oncology, Inc. CTOR R&D capitalization
R&D capitalization at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s r&d capitalization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s r&d capitalization?
- Citius Oncology, Inc. (CTOR) reported r&d capitalization of $2.78M in Q3 2025.
- What is the long-term trend for Citius Oncology, Inc.'s r&d capitalization?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s r&d capitalization has grown at a 55.5% compound annual growth rate (CAGR), from $1.15M to $2.78M.
- What does r&d capitalization mean?
- This metric tracks the tax impact of capitalizing research and development expenses for financial reporting purposes while potentially expensing them for tax purposes. It represents a temporary difference between the book value and tax basis of R&D-related investments. Investors use this to understand the timing of tax obligations related to the company's R&D spending strategy.